NSCLC Videos

Corey Langer, MD, Abramson Cancer Center

Videos

How to Handle Elderly Patients and Individuals With Performance Status 2 and NSCLC

06/14/2023

At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...

At the 2023 Great Debates and...

06/14/2023

Oncology

Kim Norris, Lung Cancer Foundation of America

Videos

Understanding and Employing Patient Advocacy

05/16/2023

At the 2023 Great Debates and Updates conference in Chicago Illinois, Kim Norris, co-founder and president of the Lung Cancer Foundation of America, discussed the different types of patient advocacy and the effect advocacy can have on...

At the 2023 Great Debates and...

05/16/2023

Oncology

Edward Garon, MD, University of California Los Angeles

Videos

Frontline Management of NSCLC After Approval of Durvalumab Plus Tremelimumab and Chemotherapy

12/22/2022

Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss options for frontline management of NSCLC after the most recent approval of durvalumab plus tremelimumab and chemotherapy based on results from the POSEIDON trial.

Edward Garon, MD, and Lyudmila...

12/22/2022

Oncology

Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute

Videos

How to Handle Patients With PD-L1 >50% Non-Small Cell Lung Cancer

12/13/2022

Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.

Leena Gandhi, MD, PhD, discusses...

12/13/2022

Oncology

Mark Awad, MD, PhD, Dana-Farber Cancer Institute

Videos

Overcoming Resistance to Checkpoint Inhibitors in Lung Cancer

12/13/2022

Dr Mark Awad reviews his presentation at the 2022 Great Debates and Updates in Lung Cancer meeting in New York which focused on the management of patient resistance to checkpoint inhibitors.

Dr Mark Awad reviews his...

12/13/2022

Oncology

Videos

Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC

06/03/2020

Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with NSCLC.

Solange Peters, MD, PhD,...

06/03/2020

Oncology

Videos

Recent Advancements in the Treatment of HER2+ NSCLC

06/01/2020

Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.

Solange Peters, MD, PhD,...

06/01/2020

Oncology

Videos

Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC

06/01/2020

Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.

Yasir Elamin, MD, talks about...

06/01/2020

Oncology

Videos

Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC

05/31/2020

Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.

Yasir Elamin, MD, talks about...

05/31/2020

Oncology

Videos

Experts Identify Mutational Biomarker for Poor Prognosis in ALK+ NSCLC

05/30/2020

David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.

David Carbone, MD, PhD, comments...

05/30/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology